-
1 month ago | 
zacks.com | Ekta Bagri
Shares of AC Immune ( - Free Report) have lost 18.3% in the past month compared with the industry’s decline of 1.3%. The stock has underperformed the sector and the S&P 500 Index during this timeframe. Earlier in the month, ACIU reported better-than-expected results for the fourth quarter. Nonetheless, shares of this Switzerland-based clinical-stage biopharmaceutical company continue to slide down.
-
1 month ago | 
zacks.com | Ekta Bagri
Shares of Pacira BioSciences ( - Free Report) have surged 66.8% in the past six months against the industry’s decline of 8.7%. The stock has also outperformed the sector and the S&P 500 index during this timeframe. Strong quarterly results, consistent growth in sales of lead drug Exparel and encouraging pipeline progress have boosted investor sentiment.
-
1 month ago | 
zacks.com | Ekta Bagri
Shares of Harmony Biosciences ( - Free Report) have lost 10.8% in the past six months compared with the industry’s decline of 9.7%. The stock has also underperformed the S&P 500 index during this timeframe. The stock was hit last month after the company announced that it received a Refusal to File (RTF) letter from the FDA for pitolisant for the treatment of excessive daytime sleepiness (EDS) in adult patients with idiopathic hypersomnia (IH).
-
1 month ago | 
zacks.com | Ekta Bagri
Gilead Sciences, Inc. ( - Free Report) hit a 52-week high of $119.96 on March 10. The stock is currently trading at $111.44. Shares have also gained 5.5% in the past month compared with the industry’s growth of 1.2%. The stock has outperformed the sector and the S&P 500 Index in this timeframe. Positive data readouts and encouraging pipeline progress have boosted investors’ sentiment.
-
1 month ago | 
zacks.com | Ekta Bagri
Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb ( - Free Report) agreed to acquire 2seventy bio, Inc ( - Free Report) . Meanwhile, other pipeline and regulatory updates were in focus. Recap of the Week’s Most Important Stories:TSVT Stock Up on BMY Deal for $286MShares of 2seventy bio gained after it announced a definitive merger agreement with partner BMY.
-
1 month ago | 
zacks.com | Ekta Bagri
Shares of Bristol Myers ( - Free Report) have risen 9.2% in the past month compared with the medical biomedical and genetics industry’s growth of 5%. The stock has also outperformed the industry and the sector during this timeframe. Last month, BMY reported better-than-expected results for the fourth quarter. However, the outlook for 2025 was a dampener. BMY expects revenues of approximately $45.5 billion in 2025, down from $48.3 billion reported in 2024.
-
1 month ago | 
zacks.com | Ekta Bagri
Rigel Pharmaceuticals, Inc. ( - Free Report) is set to report its fourth-quarter and full-year 2024 earnings on March 4. The Zacks Consensus Estimate for sales and earnings is pegged at $57.57 million and 42 cents per share, respectively. The Zacks Consensus Estimate for 2024 earnings per share (EPS) has increased to 22 cents from 17 cents over the past 60 days. The EPS estimate for 2025 has also jumped 13 cents to $1.05. Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
-
1 month ago | 
zacks.com | Ekta Bagri
Shares of biotechnology company Rigel Pharmaceuticals, Inc. ( - Free Report) have surged 41.4% in the past year against the industry’s decline of 13.4%. The stock also outperformed the sector and S&P 500 Index during this time frame. The outperformance can be attributed to the strong growth of leading drug, Tavalisse, and an impressive pipeline progress.
-
2 months ago | 
zacks.com | Ekta Bagri
Last week, Exelixis, Inc. ( - Free Report) reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which beat the Zacks Consensus Estimate of 51 cents. The company registered adjusted earnings of 33 cents per share in the year-ago quarter. The outperformance was mainly driven by higher revenues. Including stock-based compensation expense, earnings were 48 cents per share in the reported quarter.
-
2 months ago | 
zacks.com | Ekta Bagri
Last week, Gilead Sciences, Inc. ( - Free Report) reported better-than-expected fourth-quarter results. Adjusted earnings per share (EPS) of $1.90 beat the Zacks Consensus Estimate of $1.67. In the year-ago quarter, the company reported EPS of $1.72. The year-over-year increase in EPS was driven by higher product sales and lower acquired IPR&D expenses. Total revenues of $7.6 billion comfortably beat the Zacks Consensus Estimate of $7.1 billion.
